ATNM
HEALTHCAREActinium Pharmaceuticals Inc
$1.24-0.02 (-1.59%)PRE
Live · AMEX · May 9, Close
AI Insight
What's Moving ATNM Today?
No stock-specific AI insight has been generated for ATNM yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.95$1.95
$1.24
Fundamentals
Market Cap$39M
P/E Ratio—
EPS$-1.09
Dividend Yield—
Dividend / Share—
ROE-1.7%
Profit Margin—
Debt / Equity—
Trading
Volume148K
Avg Volume (10D)—
Shares Outstanding31.4M
ATNM News
20 articles- Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate OptimizationYahoo Finance·May 6, 2026
- Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual MeetingYahoo Finance·Apr 22, 2026
- Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual MeetingYahoo Finance·Apr 22, 2026
- Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual MeetingYahoo Finance·Apr 6, 2026
- Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual MeetingYahoo Finance·Feb 17, 2026
- Are Medical Stocks Lagging Actinium Pharmaceuticals (ATNM) This Year?Yahoo Finance·Dec 22, 2025
- Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025Yahoo Finance·Dec 12, 2025
- Are Medical Stocks Lagging Alpha Cognition Inc. (ACOG) This Year?Yahoo Finance·Dec 5, 2025
- Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer SymposiumYahoo Finance·Dec 1, 2025
- Is Alpha Cognition Inc. (ACOG) Stock Outpacing Its Medical Peers This Year?Yahoo Finance·Nov 19, 2025
- Actinium: Q3 Earnings SnapshotYahoo Finance·Nov 14, 2025
- Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor IndicationsYahoo Finance·Nov 4, 2025
- Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat ConferenceYahoo Finance·Nov 3, 2025
- Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsYahoo Finance·Oct 27, 2025
- Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific RetreatYahoo Finance·Oct 24, 2025
- Sector Update: Health Care Stocks Advance Monday AfternoonYahoo Finance·Oct 13, 2025
- Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsYahoo Finance·Oct 13, 2025
- Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific RetreatYahoo Finance·Oct 13, 2025
- Is Armata Pharmaceuticals (ARMP) Stock Outpacing Its Medical Peers This Year?Yahoo Finance·Sep 18, 2025
- Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year?Yahoo Finance·Sep 2, 2025
All 20 articles loaded
Price Data
Open$1.30
Previous Close$1.26
Day High$1.30
Day Low$1.23
52 Week High$1.95
52 Week Low$0.95
52-Week Range
$0.95$1.95
$1.24
Fundamentals
Market Cap$39M
P/E Ratio—
EPS$-1.09
Dividend Yield—
Dividend / Share—
ROE-1.7%
Profit Margin—
Debt / Equity—
Trading
Volume148K
Avg Volume (10D)—
Shares Outstanding31.4M
About Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplantation (BMT) or a type of cell therapy, and for other adoptive cell therapies. The company is headquartered in New York, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeAMEX
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—